Influence of the SLCO1Bl*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 373, Issue 1, 2006, Pages 45-50

  Gerloff, Thomas ^a,b   Schaefer, Melanie ^a,b   Mwinyi, Jessica ^a   Johne, Andreas ^a   Sudhop, Thomas ^c   Lütjohann, Dieter ^c   Roots, Ivar ^a,b   Von Bergmann, Klaus ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Cenimed GmbH   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Bile acids; HMG CoA reductase inhibition; Lathosterol; Nuclear receptor; Oxysterols; Pharmacogenetics; SLCO1B1

Indexed keywords

CAMPESTEROL; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LATHOSTEROL; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 5; PRAVASTATIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PHYTOSTEROL; SLCO1B1 PROTEIN, HUMAN;

ADULT; ARTICLE; CAMPESTEROL BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME INHIBITION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOSITY; HUMAN; LATHOSTEROL BLOOD LEVEL; LIPID BLOOD LEVEL; LIVER CLEARANCE; MALE; NORMAL HUMAN; PHARMACOGENETICS; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; BLOOD; GENETICS; MIDDLE AGED;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; PHYTOSTEROLS; PRAVASTATIN;

EID: 33645876499     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-006-0053-6     Document Type: Article

References (24)

1. Chiang JYL (1998) Regulation of bile acid synthesis. Front Biosci 3:D176-D193
2. Fuchs M (2003) Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am J Physiol Gastrointest Liver Physiol 284:G551-G557
3. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6:517-526
4. Gupta S, Pandak WM, Hylemon PB (2002) LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem Biophys Res Commun 293:228-243
5. Hagenbuch B, Meier PJ (1996) Sinusoidal (basolateral) bile salt uptake systems of hepatocytes. Semin Liver Dis 16:129-136
6. Hatanaka T (2000) Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 39:397-412
7. Hofmann AF (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159:2647-2658
8. Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, Suzuki H, Sugiyama Y (1998) Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther 287:37-42
9. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533
10. Marzolini C, Tirona RG, Kim RB (2004) Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5:273-282
11. Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum M, Keppler D, Konig J (2002) A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 277:43058-43063
12. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T (2004) Evidence for inverse effects of OATP1B1 (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75:415-421
13. Myant NB, Mitropoulos KA (1977) Cholesterol 7α-hydroxylase. J Lipid Res 18:135-153
14. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, Nishimura K (2001) Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861-867
15. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivisto KT (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP1B1, SLCO1B1). Pharmacogenetics 14:429-440
16. Niemi M, Neuvonen PJ, Hofmann U, Backmann JT, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and Genomics 15:303-309
17. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-65
18. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allelic frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804-13
19. Schroepfer JG (2000) Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev 80:361-554
20. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K (2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106:1943-1948
21. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T (2004) Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19:375-380
22. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A (2001) Functional characterization of human organic anion transporting polypeptide B (OATP1B1) in comparison with liver-specific OATP1B1. Pharm Res 18:1262-1269
23. Tamasawa N, Hayakari M, Murakami H, Matsui J, Suda T (1997) Reduction of oxysterol levels up-regulates HMG-CoA reductase activity in rat liver. Atherosclerosis 131:237-242
24. Tirona RG, Leake BF, Merino G, Kim RB (2001) Polymorphisms in OATP1B1: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669-35675